Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Dechra Pharmaceuticals PLC    DPH   GB0009633180

DECHRA PHARMACEUTICALS PLC

(DPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/19/2021 01/20/2021 01/21/2021 01/22/2021 01/25/2021 Date
3662(c) 3664(c) 3648(c) 3672(c) 3716(c) Last
163 034 233 089 262 115 145 420 344 765 Volume
+0.49% +0.05% -0.44% +0.66% +1.20% Change
More quotes
Financials
Sales 2021 576 M 786 M 786 M
Net income 2021 47,1 M 64,3 M 64,3 M
Net Debt 2021 165 M 226 M 226 M
P/E ratio 2021 88,9x
Yield 2021 1,00%
Sales 2022 621 M 848 M 848 M
Net income 2022 59,4 M 81,1 M 81,1 M
Net Debt 2022 94,5 M 129 M 129 M
P/E ratio 2022 71,1x
Yield 2022 1,08%
Capitalization 4 019 M 5 486 M 5 487 M
EV / Sales 2021 7,27x
EV / Sales 2022 6,62x
Nbr of Employees -
Free-Float 98,3%
More Financials
Company
Dechra Pharmaceuticals specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (70.6%); - food producing animal products (11.9%); - equine health products (7.2%); - animal feeds (6%); - other (4.3%): products manufactured by third parties. Net sales are distributed geographically as follows: the... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Notations Surperformance© of Dechra Pharmaceuticals PLC
Trading Rating : Investor Rating :
More Ratings
All news about DECHRA PHARMACEUTICALS PLC
01/14DECHRA PHARMACEUTICALS : On Track to Surpass FY21 Estimates As Interim Revenue G..
MT
2020DECHRA PHARMACEUTICALS PLC : Ex-dividend day for final dividend
FA
2020DECHRA PHARMACEUTICALS : Preliminary Results Presentation for the year ended 30 ..
PU
2020EUROPE : European shares kick of week on strong footing, vaccine progress eyed
RE
2020European shares end higher for first time in three sessions
RE
2020DECHRA PHARMACEUTICALS PLC : annual earnings release
2020Elanco Animal Health wins approval to buy Bayer unit
RE
2020DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..
CO
2020DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..
CO
2020DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..
CO
2020KINDRED BIOSCIENCES : Announces Completion of Mirataz Transaction
AQ
2020DECHRA PHARMACEUTICALS : Kindred Biosciences Announces Completion of Mirataz® (m..
PR
2020DECHRA PHARMACEUTICALS PLC : Monthly statement on outstanding equity shares and ..
CO
2020KINDRED BIOSCIENCES : Announces Mirataz Transaction and Reports Fourth Quarter a..
AQ
2020DECHRA PHARMACEUTICALS : acquires worldwide rights to Mirataz (R)
PU
More news
News in other languages on DECHRA PHARMACEUTICALS PLC
2020Déjà pliée, cette élection ?
2020AVIS D'ANALYSTES DU JOUR : Air Liquide, Continental, Galapagos, Logitech, Superd..
2020EN DIRECT DES MARCHES : Sanofi, Renault, Suez, Natixis, Solocal, AB Science, Tes..
2020La baleine du Nasdaq ?
2020DECHRA PHARMACEUTICALS PLC : publication des résultats annuels
More news
Chart DECHRA PHARMACEUTICALS PLC
Duration : Period :
Dechra Pharmaceuticals PLC Technical Analysis Chart | DPH | GB0009633180 | MarketScreener
Technical analysis trends DECHRA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 3 598,00 GBX
Last Close Price 3 716,00 GBX
Spread / Highest target 14,4%
Spread / Average Target -3,18%
Spread / Lowest Target -24,7%
EPS Revisions
Managers and Directors
NameTitle
Ian David Page Chief Executive Officer & Executive Director
William Anthony Rice Non-Executive Chairman
Paul Sandland Chief Financial Officer & Executive Director
Susan Longhofer Chief Scientific Officer
Allen Mellor Director-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
DECHRA PHARMACEUTICALS PLC7.71%5 486
ZOETIS-1.31%77 625
ELANCO ANIMAL HEALTH INCORPORATED-0.68%14 375
JINYU BIO-TECHNOLOGY CO., LTD.2.39%3 649
VIRBAC-8.82%2 259
VÉTOQUINOL SA3.35%1 288